

UNCLASSIFIED

AD NUMBER
ADB225820
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; May 97. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, MD 21702-5012.
AUTHORITY
USAMRMC ltr, 26 Jan 01.

THIS PAGE IS UNCLASSIFIED

AD _____

GRANT NUMBER DAMD17-96-1-6008

TITLE: DNA Topoisomerase I-Targeted Therapy for Breast Cancer

PRINCIPAL INVESTIGATOR: Daniel D. Von Hoff, M.D.
Shih-Fon Chen, Ph.D.

CONTRACTING ORGANIZATION: CTRC Research Foundation
San Antonio, Texas 78229-3264

REPORT DATE: June 1997

TYPE OF REPORT: Annual

PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, May 97). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19970711 099

DTIC QUALITY INSPECTED 3

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.				
1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE June 1997	3. REPORT TYPE AND DATES COVERED Annual (6 May 96 - 5 May 97)		
4. TITLE AND SUBTITLE DNA Topoisomerase I-Targeted Therapy for Breast Cancer		5. FUNDING NUMBERS DAMD17-96-1-6008		
6. AUTHOR(S) Von Hoff, Daniel D., M.D. Chen, Shih-Fon, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) CTRC Research Foundation San Antonio, Texas 78229-3264		8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research Command Fort Detrick, Maryland 21702-5012		10. SPONSORING / MONITORING AGENCY REPORT NUMBER		
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Distribution authorized to U.S. Government agencies only (proprietary information May 97). Other requests for this document shall be referred to Commander, U.S. Army Medical Research and Materiel Command, ATTN: MCMR-RMI-S, Fort Detrick, Frederick, MD 21702-5012.			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) Camptothecin analogues have been developed that show enhanced pre-clinical activity against breast cancer cells. These analogues have been synthesized with two fundamental modifications that aid in their effectiveness against breast cancer: (i) they have a glycinate ester of the 20(S)-OH group, which aids in both solubility and stabilization of the drug's lactone ring; and (ii) they possess a 9-chloro substitution, which allows them to covalently link to DNA. We have studied the activity of these compounds against breast cancer cells in a series of <i>in vitro</i> tests: growth inhibitory activity, clonogenic survival assays, and inhibition of topoisomerase I catalytic activity. The new analogues, in both growth inhibition and clonogenic assays, are substantially more effective against breast cancer cells than those topoisomerase inhibitors currently being used clinically. Further, the new analogues are potent topoisomerase I inhibitors. Our results indicate that these new camptothecin analogues possess promising activity as potential clinically useful agents against breast cancer.				
14. SUBJECT TERMS Breast Cancer			15. NUMBER OF PAGES 15	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Limited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

DVA Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

DVA In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

DVA For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

QO RUM
PI - Signature

5/2/97
Date

TABLE OF CONTENTS

A.	INTRODUCTION.....	2
A.1	Cancers, Camptothecin and Topoisomerase I.....	2
A.2	Irinotecan and Topotecan.....	2
A.3	Design Novel CPT Analogs with Better Therapeutic Advantages over Irinotecan or Topotecan.....	2
A.4	Hypothesis/Purpose.....	3
B.	BODY.....	3
B.1	Compounds of Interest.....	3
B.2	Cell Culture.....	4
B.3	In Vitro Growth Inhibitory Activity	4
B.4	Clonogenic Survival Assay	4
B.5	Inhibition of Topoisomerase I Catalytic Activity	5
B.6	Results	5
B.6.1	Growth Inhibitory Activity of CPT Analogs	5
B.6.2	Growth Inhibitory Activity Against CPT-Resistant P388 Cell Line.....	6
B.6.3	Clonogenic Survival of Tumor Cells Treated with RTI Camptothecin Analogs	7
B.6.4	Inhibition of the Topo I Catalytic Activity by CPT Analogs.....	7
C.	CONCLUSIONS	8
D.	REFERENCES	9

DTIC QUALITY INSPECTED 8

A. INTRODUCTION

A.1 Cancers, Camptothecin and Topoisomerase I

Cancer is the second leading cause of death (just behind cardiovascular diseases) in the United States. More than one million people are diagnosed with cancer and about half of them die each year in the United States. Surgery, radiation and chemotherapy are the three major modalities for the treatment of cancer. Surgery and radiation are very effective in the removal of tumor locally. Since cancer is a disseminated disease, chemotherapy is generally needed for the treatment of metastatic diseases. Although there have been many advances in cancer treatments and many success stories, the most common cancers — breast, colon, lung and prostate — remain rather refractory to treatment.

In 1966, Dr. Monroe Wall and colleagues discovered that camptothecin (CPT) was the active principal of the extract from the stem of the Chinese tree *Camptotheca acuminata* (1). CPT had significant antitumor activity against L1210 murine leukemia (1). Early clinical trials with CPT in the late 1960s showed that this plant alkaloid had activity against a variety of solid tumors (2-4). However, further development was discontinued because of unpredictable and severe myelosuppression, gastrointestinal toxicity and hemorrhagic cystitis.

Further development of topoisomerase I (topo I) inhibitors for cancer therapy was stimulated by the characterization of CPT as a specific topo I inhibitor (5, 6). Eukaryotic topo I engages DNA in a cycle of breakage and religation steps. These topological adjustments are important in local DNA unwinding during DNA synthesis, repair, and transcription. Topo I relaxes DNA supercoiling by making transient single-strand breaks (7, 8). These breaks are coupled with the transient formation of a covalent DNA-enzyme intermediate termed the cleavable complex (5). CPT specifically and reversibly stabilizes cleavable complexes by inhibiting their religation. The mechanism of CPT cytotoxicity is thought to be the consequence of a collision between moving replication forks and CPT-stabilized cleavable DNA-topo I complexes (9-11).

A.2 Irinotecan and Topotecan

There are several topo I inhibitors at various stages of clinical development. Of these, irinotecan (CPT-11) and topotecan have been approved by the Food and Drug Administration. CPT-11 is a pro-drug and must be converted to SN38 by carboxylesterase to exert its antitumor activity (12, 13). Neutropenia and diarrhea are the dose-limiting toxicities of CPT-11 (depending on the schedule) (14, 15). Thrombocytopenia is the dose-limiting toxicity for topotecan (16). CPT-11 has shown antitumor activity in phase II trials for patients with carcinoma of the colon, lung, cervix, and ovary, as well as for patients with non-Hodgkin's lymphoma. Topotecan has demonstrated clinical antitumor activity against advanced small cell lung, ovarian, and non-small cell lung cancers (14, 15). Irinotecan has recently been approved for the second-line treatment of metastatic colorectal cancer in the U.S. and Europe and for other additional indications in Japan. Topotecan was approved for the treatment of patients with ovarian cancer that is refractory to the platinum analogs.

A.3 Design Novel CPT Analogs With Better Therapeutic Advantages Over Irinotecan or Topotecan

Based on several new findings from our collaborative studies with Dr. Wall of the Research Triangle Institute (RTI), we have developed several approaches for the design of DNA topo I-targeted agents and have identified a number of new CPT analogs that we feel have promise as agents with activity against various forms of cancer. There are three potential ways that one might improve the antitumor activity of DNA topo I-targeted agents. We proposed that analogs that have improved lactone stability, could form an irreversible DNA-topo I cleavable complex, and are not cross-resistant to topotecan and irinotecan will be useful in the treatment of human cancers.

It has been well documented that the intact lactone ring of CPT is required for antitumor activity (17-21). We have extensive preclinical and clinical experience working with both irinotecan and topotecan at the Institute for Drug Development. We have documented that both topotecan and irinotecan are inactivated in patients by hydrolysis of the lactone ring (16). Continuous exposure to

either irinotecan or topotecan increases antitumor activity against human tumor colony-forming units (15). Further support of this hypothesis comes from the preliminary hint of activity of topotecan in patients with advanced breast cancer using a 21-day continuous administration schedule (22). All of these results suggest that a CPT analog with greater lactone stability would be an even better antitumor agent.

The second method that may improve the antitumor activity of CPT analogs comes from our most recent data and is based on generating an irreversible DNA-topo I cleavable complex. Normally, the trapping of DNA-topo I cleavable complexes by CPT analogs is rapid and reversible. Dr. Wall has designed the compound 7-chloromethyl-10,11-MD-20(S)-OH CPT (RT006) which could form an irreversible DNA-topo I cleavable complex (23). We have found that at equal concentrations, Dr. Wall's compound kills more tumor cells than are killed by CPT, which produces a reversible cleavable complex. Therefore, this is an exciting strategy that we will pursue further in this proposal as we seek to enhance the activity of CPT analogs against human cancers.

A.4 Hypothesis/Purpose

Our hypothesis is that CPT analogs will have better clinical antitumor activity than irinotecan or topotecan if those CPT analogs (i) have a more stable lactone ring, (ii) are capable of forming an irreversible cleavable DNA-topo I complex, and/or (iii) are not cross-resistant to irinotecan or topotecan.

B. BODY


B.1 Compounds of Interest

We have specifically designed and synthesized (with Dr. Wall and his colleagues at the Research Triangle Institute) compound RT019, 7-chloromethyl-10,11-methylenedioxy-20(S)-O-glycinate CPT•HCl, that could fulfill the requirement of being an analog of choice. RT019 contains a 7-chloromethyl group that could trap DNA-topo I cleavable complexes irreversibly and a 20(S)-O-glycinate group that could protect the lactone ring from undergoing pH-dependent hydrolysis. To test our hypothesis, we also prepared and evaluated the following model compounds for comparison:

- RT006: 7-chloromethyl-10,11-methylenedioxy-20(S)-OH CPT
- RT010: 7-ethyl-10,11-methylenedioxy-20(S)-OH CPT
- RT017: 7-ethyl-10,11-methylenedioxy-20(S)-O-glycinate CPT•HCl

RT006 is the parent compound of RT019. RT010 and RT017 contain a 7-ethyl group which theoretically will not form an irreversible DNA-topo I cleavable complex. The chemical structures of these compounds are shown in Fig. 1.

Fig.1 Chemical Structure of RT006, RT010, RT017, and RT019



B.2 Cell Culture

Murine **B16** melanoma cell line was grown in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 50 units/ml penicillin, 50 µg/ml streptomycin, 25 µg/ml gentamycin, 0.75% sodium bicarbonate, 10 mM HEPES buffer (pH 7.4), and 0.06 mg/ml AntiPPLO. Murine **P388** leukemic cell line and human **HT-29** colon adenocarcinoma line were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum. **P388/CPT** (camptothecin-resistant murine leukemic P388 cell line) was maintained in RPMI 1640 medium supplemented with 20% heat-inactivated fetal bovine serum, 10 µM β-mercaptoethanol, 10 mM L-glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin, and 50 µg/ml gentamycin. **MCF-7M** human breast adenocarcinoma was maintained in IMEM medium supplemented with 5% non-heat-inactivated fetal bovine serum and 1 nM insulin. **DU145** human prostate carcinoma was maintained in EMEM medium supplemented with 10% non-heat-inactivated fetal bovine serum and 2 mM L-glutamine. **HS578T** human ductal carcinoma was maintained in IMEM medium supplemented in 10% heat-inactivated fetal bovine serum and 10⁻⁸ M Insulin. **PC3** human prostate adenocarcinoma was maintained in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum and 2 mM L-glutamine.

B.3 In Vitro Growth Inhibitory Activity

Exponentially growing cells (1-2 x 10³ cells, unless otherwise specified) in 0.1 ml medium were seeded on day 0 in a 96-well microtiter plate. On day 1, 0.1 ml aliquots of medium containing graded concentrations of test analogs were added in duplicate to the cell plates. After incubation at 37 °C in a humidified incubator with 5% CO₂-95% air for 3 days (P388, P388/CPT, B16, HS578T, SK-MES) or 6 days (HT-29, MCF-7M, DU145, PC-3), the plates were centrifuged briefly and 100 µl of the growth medium was removed. Cell cultures were incubated with 50 µl of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide [MTT, 1 mg/ml in Dulbecco's phosphate buffered saline (PBS)] for 4 hr at 37 °C. The resulting purple formazan precipitate was solubilized with 200 µl of 0.04 N HCl in isopropyl alcohol. Absorbance was monitored in a BioRad Model 3550 Microplate Reader at a test wavelength of 570 nm and a reference wavelength of 630 nm. The absorbance was transferred to a PC 486 computer. The IC₅₀ values were determined by a computer program (EZ-ED50) (Perrella Scientific, Inc.) that fits all of the data to the following four-parameter logistic equation:

$$Y = \frac{A_{\max} - A_{\min}}{1 + (X/IC_{50})^n} + A_{\min}$$

where $A_{\max}$ is the absorbance of control cells, $A_{\min}$ is the absorbance of cells in the presence of highest agent concentration, Y is the observed absorbance, X is the agent concentration, IC_{50} is the concentration of agent that inhibits the cell growth by 50% of control cells (based on the absorbance) and n is the slope of the curve.

B.4 Clonogenic Survival Assay

The MTT assay (described in D.2) measures the ability of the cells to metabolize the MTT; it can determine whether tumor cell growth is inhibited but cannot distinguish whether an agent is cytostatic or cytotoxic. We also evaluated the antitumor activity of selected agents by the clonogenic survival assay which measures the ability of tumor cells to form colonies. The tumor cells which survive the drug treatment will continue to proliferate and form a colony with more than 50 cells/colony.

Cultured human breast tumor (MCF-7) cells were exposed to graded concentrations of selected DNA topo I-targeted agents for 1 hr. The cells were harvested by trypsin treatment. The cell pellets were washed twice (to remove residual test agent) with 5 ml medium and were resuspended in growth medium, and the cell concentrations were adjusted for appropriate seeding density. The cells were then replated in fresh medium and incubated at 37 °C for at least six cell doublings, so that more than 50 cells/colony were formed in the control. The cultures were washed with saline and stained with crystal violet (0.5% crystal violet in absolute ethanol). The number of colonies with more than 50 cells/colony were counted. The plating efficiency (PE) was calculated as the percentage of the number

of colonies formed from the total number of cells seeded. Cell survival was calculated as the ratio of plating efficiency of the DNA-topo I targeted agent-treated cells *versus* that of untreated control cells (34, 35).

B.5 Inhibition of Topoisomerase I Catalytic Activity

The topoisomerase I catalytic activity was measured by converting the supercoiled SV40 DNA (Form I) to the relaxed form (Form I₀). All reactions were performed in 20 µl reaction buffer (Tris-HCl, 10 mM, pH 7.5; EDTA, 1 mM; NaCl, 100 mM) with 0.25 µg SV40 DNA, 0.5 unit of human placental topoisomerase I (TopoGen) or calf thymus topoisomerase I (Gibco BRL) and graded concentrations of the analog tested. The reaction mixtures were incubated at 37 °C for 30 min. The topoisomerase I activity was stopped by incubating the reaction mixture with 1 µl of 10% SDS and 1 µl of proteinase K (1.25 mg/ml) for an additional 30 min. One microliter of the loading buffer (1% bromophenol blue and 48% sucrose) was then added. Ten microliters of the reaction mixture were loaded onto a 1% agarose gel prepared in the TAE buffer. The electrophoresis was performed at 82 volts for 3.5 hr in TAE buffer. Another 10 µl of the reaction mixture was loaded onto a 1% agarose gel prepared in TAE buffer containing 2 µg/ml chloroquine; the electrophoresis was performed at 82 volts for 4.5 hr in the TAE buffer containing 2 µg/ml chloroquine. Chloroquine is added to separate nicked and relaxed DNA molecules; without chloroquine, the fully relaxed Form I₀ DNA comigrates with the nicked DNA. The gels were then stained with 0.5 µg/ml ethidium bromide solution for 30 min or longer (if chloroquine was present during the electrophoresis step), and destained with 5 changes of deionized water. DNA bands were visualized with a 254 nm uv light (Spectroline Transilluminator Model TL-254A) and documented with Polaroid 665 positive/negative instant pack film. The DNA bands (image) on the negative were densitometrically scanned with a Molecular Dynamic Personal Densitometer. The percent inhibition of topoisomerase I activity is calculated based on the following equation:

$$\%Inhibition = \frac{F_{SC_{E+D}} - F_{SC_E}}{F_{SC_C} - F_{SC_E}} \times 100$$

where $F_{SC_{E+D}}$ represents the fraction of supercoiled DNA in the presence of enzyme and drug; F_{SC_E} represents the fraction of supercoiled DNA in the presence of enzyme alone; and F_{SC_C} represents the fraction of supercoiled DNA in the untreated SV40 DNA. The IC₅₀ value (concentration of drug that inhibits 50% of topoisomerase I activity) was estimated using the same four-parameter logistic equation described in the *in vitro* growth inhibition studies (Section B.3).

B.6 Results

B.6.1 Growth Inhibitory Activity of CPT Analogs

We have found that these two pairs of 20(S)-OH analogs and their corresponding 20(S)-O-glycinate analogs (RT010 *versus* RT017 with a 7-ethyl group, and RT006 *versus* RT019 with a 7-chloromethyl group) have potent and comparable *in vitro* growth inhibitory activity against several cultured murine and human tumor cell lines, including murine leukemia and melanoma as well as human breast, colon, prostate and lung cancer cell lines (Table 1). The growth inhibitory activities of these compounds are at least one to two logs more potent than topotecan or SN38 and at least three logs more potent than irinotecan. The differential cytotoxicity (100-fold) between irinotecan and SN38 is not unexpected, since irinotecan is known as a pro-drug and must be converted to SN38 to exert its cytotoxicity. The data suggest irinotecan is slowly and inefficiently converted (if at all) to SN38 in the presence of cultured tumor cells. On the other hand, the finding that the 20(S)-O-glycinate CPTs and their parent 20(S)-OH CPTs have equivalent growth inhibitory activity (Table 1) suggests that either (i) 20(S)-O-glycinates are active drugs in their own right or (ii) 20(S)-O-glycinates are converted efficiently to 20(S)-OH compounds in the presence of cultured tumor cells.

It is also of interest to note that the 7-ethyl analogs (RT010 and RT017) are generally two to five fold more cytotoxic to cells than the 7-chloromethyl analogs (RT006 and RT019). These results are somewhat surprising and contradictory to what we expected. Based on their mechanism, we expected

that CPT analogs which could trap DNA-topo I cleavable complexes irreversibly would be more cytotoxic. Since tumor cells were incubated continuously with CPT analogs in these studies, the MTT assay may not be able to distinguish the growth inhibitory activity of CPT analogs which trap the DNA-topo I cleavable complex reversibly (RT010, RT017) from those which trap the DNA-topo I cleavable complex irreversibly (RT006, RT019).

Table 1. Growth Inhibitory Activity of RTI Camptothecin Analogs and Standard Agents Against Selected Cultured Murine and Human Tumor Cell Lines

Cell Line	Growth Inhibitory Activity (IC ₅₀ ; nM)						
	RT010	RT017	RT006	RT019	Irinotecan	SN38	Topotecan
B16	0.8 ± 0.1	1.8 ± 0.2	4.6 ± 0.5	8.6 ± 2.3	5148 ± 2828	12 ± 4	63 ± 26
DU145	0.3 ± 0.1	0.4 ± 0.2	1.1 ± 0.6	3.4 ± 1.5	1268 ± 326	3.5 ± 0.5	17 ± 10
HS578T	0.5 ± 0.2	0.7 ± 0.4	1.2 ± 0.1	3.9 ± 1	2165 ± 368	3.3 ± 1	23 ± 1
HT29	0.3 ± 0.1	0.5 ± 0.1	1.3 ± 0.1	2.9 ± 0.4	1552 ± 203	4.6 ± 0.2	24 ± 3
MCF7	53 ± 80	57 ± 90	0.6 ± 0.2	1.2 ± 0.5	88 ± 174	1.3 ± 0.4	12 ± 1
PC3	0.2 ± 0.2	0.3	0.9	nt	15	2.4	nt
SK-MES	0.6 ± 0.2	0.9 ± 0.2	2.3 ± 0.8	5.2 ± 0.7	3253	10 ± 3.7	52 ± 12

B.6.2 Growth Inhibitory Activity Against CPT-Resistant P388 Cell Line

We evaluated the growth inhibitory activity of these CPT analogs against the P388 parental and P388/CPT resistant cell lines. The P388/CPT cell line has been characterized to have an altered form of Topo I and is a generous gift from Dr. J. F. Riou (33). We have demonstrated that CPT is approximately 130-fold less active in the P388/CPT cell line. This cell line is 300-350-fold more resistant to topotecan and SN38 (the active form of irinotecan). However, this cell line is only 25-fold resistant to irinotecan. Since irinotecan is a pro-drug and the 50% growth inhibitory activity of irinotecan against the parental P388 line is already quite high (~4 µM), it is difficult to determine precisely the IC₅₀ value of irinotecan against the P388/CPT line. It is of interest to note that all four RTI CPT analogs are considerably more active against the resistant line (~ 7 fold) compared to topotecan and SN38.

Table 2. Growth Inhibitory Activity of RTI Camptothecin Analogs and Standard Agents against Parent and Camptothecin-Resistant P388 Cell Lines

	Growth Inhibitory Activity (IC ₅₀ , nM)		Resistance Factor*
	P388	P388/CPT	
Camptothecin	17.8 ± 3.8	2356.7 ± 133.2	132
Irinotecan	3967.7 ± 223.8	100310	25
SN38	9.7 ± 1.5	3357 ± 179.6	346
Topotecan	48.8 ± 9.6	14680 ± 8948.4	301
RT010	1.4 ± 0.3	62.4 ± 3.4	45
RT017	1.9 ± 0.3	90 ± 14.1	47
RT006	4.9 ± 1.6	236 ± 121.6	48
RT019	10.2 ± 2.9	953.4 ± 46.3	93


$$* \text{Resistance Factor (R / S)} = \frac{\text{IC}_{50} \text{ of P388 / CPT}}{\text{IC}_{50} \text{ of P388}}$$

B.6.3. Clonogenic Survival of Tumor Cells Treated With RTI Camptothecin Analogs

In order to determine whether CPT analogs (RT006, RT019) which could trap DNA-topo I cleavable complexes irreversibly are more effective anticancer agents, we performed a clonogenic survival assay. In the clonogenic survival assay, the tumor cells were incubated with CPT analogs for a short period of time (1 hr, in this study). The cells were then washed free of the tested agents, harvested, and replated in a drug-free medium. The cells were allowed to grow in the drug-free medium for an additional 10-14 days. [Note: If drug-induced lesions are reversible or easily repairable in the clonogenic assay, the fraction of cells which survive the initial drug treatment will be greater.]

In the clonogenic survival assay (Fig. 2), we found that 7-chloromethyl-10,11-methylenedioxy-20(S)-OH CPT (RT006) and 7-chloromethyl-10,11-methylenedioxy-20(S)-O-Gly CPT (RT019) killed several logs more MCF-7 (human breast cancer) cells than CPT did. In addition, RT006 and RT019 killed more MCF-7 cells than RT017 at concentrations $> 3 \mu\text{M}$. RT006 and RT019 have a reactive 7-chloromethyl group, which could form a covalent bond with a nucleophile. Pommier et al. previously demonstrated that 7-chloromethyl-10,11-methylenedioxy-20(S)-OH CPT (RT006) forms a DNA adduct only in the presence of topo I (23). These data support our hypothesis that CPT analogs with the ability to trap DNA-topo I cleavable complexes irreversibly are more cytotoxic than those which trap DNA-topo I cleavable complexes reversibly. These results also demonstrate the importance of using a clonogenic assay to measure tumor cell kill, as the MTT assay only provides a measure of tumor growth inhibition and not quantitative data on tumor cell kill.

Fig. 2 Clonogenic Survival of Human Breast Tumor MCF-7 Cells Treated with Selected CPT Analogs



B.6.4 Inhibition of the Topo I Catalytic Activity by CPT Analogs

Using the cell-free biochemical assay, we determined whether these four CPT analogs inhibit the catalytic activity of a purified topo I enzyme. The catalytic activity of topo I was measured by converting the supercoiled SV40 DNA (Form I) to the relaxed form (Form I₀). All four CPT analogs

demonstrated a concentration-dependent inhibition of topo I catalytic activity. The 20(S)-OH CPTs, RT006 (which forms an irreversible DNA-topo I cleavable complex) inhibits topo I catalytic activity 10-fold less than RT010 (which forms a reversible DNA-topo I cleavable complex). These 20(S)-OH CPT analogs (RT006 and RT010) are at least 10-fold more potent than their corresponding 20(S)-glycinate CPT analogs (RT019 and RT017) in inhibiting topo I catalytic activity. Since these studies are performed under a cell-free system and for only 30 min, 20(S)-O-glycinate hydrolysis is minimized. We conclude that 20(S)-O-glycinates may act like a pro-drug; they are at least 10-fold less potent than their corresponding 20(S)-OH CPTs in inhibiting the topo I catalytic activity. The data are not unexpected, because it has been demonstrated previously by Dr. Wall and other investigators that the 20(S)-OH group of CPT is essential for activity (17, 42). The bulky 20(S)-O-glycinate group might prevent CPT analogs from trapping DNA-topo I cleavable complexes efficiently and, thus, result in a weak inhibition of the catalytic activity of topo I.

C. CONCLUSIONS

We have specifically designed a water soluble camptothecin analog (RT019), 7-chloromethyl-10,11-methylenedioxy-20(S)-O-glycinate CPT•HCl as a potential third generation of camptothecin analogs for the treatment of patient with refractory tumors. This compound processes two essential groups: (i) a 20(S)-O-glycinate group which could protect the E-ring lactone from undergoing pH-dependent hydrolysis and (ii) a 7-chloromethyl group which can trap DNA-topo I cleavable complexes irreversibly.

We compared the biological activity of RT019 to three related compounds (i) RT006, 7-chloromethyl-10,11-methylenedioxy-20(S)-OH CPT, a parent compound of RT019, (ii) RT017, 7-ethyl-10,11-methylenedioxy-20(S)-O-glycinate CPT•HCl, a counterpart of RT019, which could not trap DNA-topo I cleavable complexes irreversibly, and (iii) RT010, 7-ethyl-10,11-methylenedioxy-20(S)-OH CPT, a parent compound of RT017. In addition, we compared the activity of these four CPT analogs with that of irinotecan and topotecan.

In this report, we investigated the growth inhibitory activity of these agents against a variety of murine and human tumor cell lines, and the mechanism of inhibiting topo I activity, by using a purified enzyme and by trapping DNA-topo I cleavable complexes.

We have found that the growth inhibitory activities of the 20(S)-O-glycinate and 20(S)-OH CPTs are remarkably similar (RT010 vs. RT017 and RT006 vs. RT019). In the growth inhibitory activity studies, the cells were incubated with testing agents continuously for 3-6 days, and the glycinate group may have been hydrolyzed in the cultured medium. Therefore, the glycinate and its parent compound exerted a similar growth inhibitory activity. On the other hand, we were surprised to find that 7-ethyl substituted analogs (RT010 and RT017) demonstrated more potent growth inhibitory activity than their corresponding 7-chloromethyl-substituted analogs (RT006 and RT019). This is somewhat perplexing, since we have speculated that compounds with a 7-chloromethyl group that can form an irreversible DNA-topo I complexes may be more potent antitumor agents. Therefore, it would be very important to understand why compounds which theoretically do not form an irreversible cleavable complex are more potent antitumor agents.

Since tumor cells were incubated continuously with testing agents in the growth inhibitory studies, it is difficult to distinguish the antitumor potential of CPT analogs which trap DNA-topo I cleavable complexes reversibly or irreversibly. We have used a clonogenic survival assay to address whether compounds with the ability to trap DNA-topo I cleavable complexes irreversibly are better antitumor agents. In the clonogenic survival assay, the cells were treated with test agents for 1 hr and were replated in drug-free medium. We found that CPT analogs (RT006 and RT019), which trap DNA-topo I cleavable complexes irreversibly, produced more extensive tumor cell kill than the CPT analog (RT017) which traps DNA-topo I cleavable complexes reversibly. I

In contrast to the results obtained in the growth inhibitory studies, we found that parental CPTs (RT010 and RT006) are one to two logs more potent than their 20(S)-O-glycinate CPTs (RT017 and

RT019) in inhibiting the topo I-catalyzed relaxation of supercoiled DNA. However, some topo I inhibition was observed with the glycinate esters at time points when hydrolysis of the glycinate ester is minimal. This suggests that the glycinate esters may also have intrinsic topo I inhibitory activity, although much less so than the hydrolyzed compounds.

Our experiments thus far suggest that our compounds RT017 and RT019 and their hydrolyzed metabolites are more potent against *in vitro* breast cancers than those topo I inhibitors currently being used clinically. This suggests that these agents may be powerful new antitumor agents for treatment of breast cancer. Our experiments over the upcoming year will focus on two aspects necessary to begin to examine these agents for possible clinical use: (1) mechanistic studies of the cellular toxicities of the compounds, and (2) the activities of the compounds in *in vivo* models of breast cancer.

D. REFERENCES

1. Wall, M. E., Wani, M. C., Cook, C. E., Palmer, K. H., MacPhail, A. T., and Sim, G. A. Plant antitumor agents. 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from *Camptotheca acuminata*, J. Am. Chem. Soc. 88: 3888-3890, 1966.
2. Gottlieb, J. A., Guarino, A. M., Call, J. B., Oliverio, V. T., and Block, J. B. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880), Cancer Chemother. Rep. 54: 461-470, 1970.
3. Muggia, F. M., Creaven, P. J., Hansen, H., Cohen, M. H., and Selawry, O. S. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC 100880): Correlation with preclinical studies, Cancer Chemother. Rep. 56: 515-521, 1972.
4. Creaven, P. J., Allen, L. M., and Muggia, F. M. Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: Relation to dose and toxicity, Cancer Chemother. Rep. 56: 573-578, 1972.
5. Hsiang, Y. H., Hertzberg, R., Hecht, S., and Liu, L. F. Camptothecin induced protein-linked DNA breaks via mammalian DNA topoisomerase I, J. Biol. Chem. 260: 14873-14878, 1985.
6. Hsiang, Y.-H., Liu, L. F., Wall, M. E., Wani, M. C., Kirschenbaum, S., Silber, R., and Potmesil, M. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogs, Cancer Res. 49: 4385-4389, 1989.
7. Champoux, J. Mechanistic aspects of type-I topoisomerases, p. 217-242. Cold Spring Harbor: Cold Spring Harbor Laboratory, 1990.
8. Wang, J. C. DNA topoisomerases: why so many, J. Biol. Chem. 266: 6659-6662, 1991.
9. Holm, C., Covey, J. M., Kerrigan, D., and Pommier, Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells, Cancer Res. 49: 6365-6368, 1989.
10. Hsiang, Y.-H., Lihou, M. G., and Liu, L. F. Arrest of DNA replication by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin, Cancer Res. 49: 5077-5082, 1989.
11. Pommier, Y., Leteurtre, F., Fesen, M., Fujimori, A., Bertrand, R., Solary, E., Kohlhagen, G., and Kohn, K. W. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors, Cancer Invest. 12: 530-542, 1994.
12. Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., and Sato, K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11, Cancer Res. 51: 4187-4191, 1991.
13. Kunitomo, T., Nitta, K., Tanaka, T., Uehara, N., Baba, H., Takeuchi, M., Yokokura, T., Sowada, S., Miyasaka, T., and Mutai, M. Antitumor activity of 7-ethyl-10-[4-piperidino)-1-

- piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin against murine tumors, *Cancer Res.* 47: 5944-5947, 1987.
14. Slichenmyer, W. J., Rowinsky, E. J., Donehower, R. C., and Kaufman, S. H. The current status of camptothecin analogues as antitumor agents, *J. Natl. Cancer Inst.* 85: 271-291, 1993.
 15. Von Hoff, D. D., Casper, J., Bradley, E., Sandbach, J., Jones, D., and Makuch, R. Association between human tumor colony forming assay results and response of an individual patient's tumor to chemotherapy, *Am. J. Med.* 70: 1027-1041, 1981.
 16. Burris, H. A., III, Awada, A., Kuhn, J. G., Eckardt, J. R., Cobb, P. W., Rinaldi, D. A., Fields, S., Smith, L., and Von Hoff, D. D. Phase I and pharmacokinetic studies on topotecan administered as a 72 or 120 h continuous infusion, *Anti-Cancer Drugs.* 5: 394-402, 1994.
 17. Hertzberg, R. P., Caranfa, M. J., Holden, K. G., Jakes, D. R., Gallagher, G., Mattern, M. R., Mong, S. M., Bartus, J. O., Johnson, R. K., and Kingsbury, W. D. Modification of the hydroxyl lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity, *J. Med. Chem.* 32: 715-720, 1989.
 18. Jaxel, C., Kohn, K. W., Wani, M. C., Wall, M. E., and Pommier, Y. Structure-activity of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and a relation to antitumor activity, *Cancer Res.* 49: 1465-1469, 1989.
 19. Giovanella, B. C., Hinz, H. R., Kozielski, A. J., Stehlin, J. S., Jr., Silber, R., and Potmesil, M. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(s)-camptothecin, *Cancer Res.* 51: 3052-3055, 1991.
 20. Wani, M. C., Ronman, P. E., Lindley, J. T., and Wall, M. E. Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogs, *J. Med. Chem.* 23: 554-560, 1980.
 21. Grochow, L. B., Rowinsky, E. K., Johnson, R., Ludeman, S., Kaufmann, S. H., McCabe, F. L., Smith, B. R., Hurowitz, L., DeLisa, A., Donehower, R. C., and Noe, D. A. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer, *Drug Metab. Dispos.* 20: 706-712, 1992.
 22. Hochster, H., Liebes, L., Speyer, J., Sorich, J., Taubes, B., Oratz, R., Wernz, J., Chachoua, A., Raphael, B., Vinci, R. Z., and Blum, R. H. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen, *J. Clin. Oncol.* 12: 553-559, 1994.
 23. Pommier, Y., Kohlhagen, G., Kohn, K. W., Leteurtre, F., Wani, M. C., and Wall, M. E. Interaction of an Alkylating Camptothecin Derivative with a DNA Base at Topoisomerase i-DNA Cleavage Sites, *Proc. Natl Acad. Sci.* 92: 8861-8865, 1995.
 24. Bellamy, W. T. and Dalton, W. S. Multidrug resistance in laboratory and clinic, *Adv. Clin. Chem.* 31: 1-61, 1994.
 25. Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., and Deeley, R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line, *Science.* 258: 1650-1654, 1992.
 26. Slapak, C. A., Fracasso, P. M., Martell, R. L., Toppmeyer, D. L., Lecerf, J. M., and Levy, S. B. Overexpression of the multidrug resistance-associated protein (MRP) gene in vincristine but not doxorubicin-selected multidrug-resistant murine erythroleukemia cells, *Cancer Res.* 54: 5607-5613, 1994.
 27. Andoh, T., Ishii, K., Suzuki, Y., Ikegami, Y., Kusunoki, Y., Takemoto, T., and Okada, K. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I, *Proc. Natl. Acad. Sci. USA.* 84: 5565-5569, 1987.

28. Gupta, R. S., Gupta, R., Eng, B., Lock, R. B., Ross, W. E., Hertzberg, R. P., Caranfa, M. J., and Johnson, R. K. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I, *Cancer Res.* 48: 6404-6410, 1988.
29. Eng, W. K., McCabe, F. L., Tan, K. B., Mattern, M. R., Hofman, G. A., Woessner, R. D., Hertzberg, R. P., and Johnson, R. K. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content, *Mol. Pharmacol.* 38: 471-480, 1990.
30. Kanzawa, F., Sugimoto, Y., Minato, K., Kasahara, K., Bungo, M., Nakagawa, K., Fujiwara, Y., Liu, L. F., and Saiji, N. Establishment of a camptothecin analogue (CPT-11) resistant cell line of human non-small cell lung cancer: Characterization and mechanism of resistance, *Cancer Res.* 50: 5919-5924, 1990.
31. Sugimoto, Y., Tsukahara, S., Oh-hara, T., Ise, T., and Tsuruo, T. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody, *Cancer Res.* 50: 6925-6930, 1990.
32. Tanizawa, A. and Pommier, Y. Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cell in culture, *Cancer Res.* 52: 1848-1854, 1992.
33. Madelaine, I., Prost, S., Naudin, A., Riou, G., Lavelle, F., and Riou, J.-F. Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation, *Biochem. Pharmacol.* 45: 339-348, 1993.
34. Chen, S. F., Behrens, D. L., Behrens, C. H., Czerniak, P. M., Dexter, D. L., Dusak, B. A., Fredericks, J. R., Gale, K. C., Gross, J. L., Jiang, J. B., Kirshenbaum, M. R., McRipley, R. J., Papp, L. M., Patten, A. D., Perrella, F. W., Seitz, S. P., Stafford, M. P., Sun, J.-H., Sun, T., Wuonola, M. A., and Von Hoff, D. D. XB596, A Promising Bis-Naphthalimide Anticancer Agent, *Anti-cancer Drugs.* 4: 447-457, 1993.
35. Chen, S. F., Ruben, R. L., and Dexter, D. L. Mechanism of action of the novel anticancer agent 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinoline carboxylic acid sodium salt (NSC 368390): Inhibition of de novo pyrimidine nucleotide biosynthesis, *Cancer Res.* 46: 5014-5019, 1986.
36. Woynarowski, J. M., Sigmund, R. D., and Beerman, T. A. Topoisomerase II-mediated lesions in nascent DNA: comparison of the effects of epipodophyllotoxin derivatives, VM-26 and VP-16, and 9-anilinoacridine derivatives, *m*-AMSA and *o*-AMSA, *Biochim. Biophys. Acta.* 950: 21-29, 1988.
37. Woynarowski, J. M., McNamee, H., Szmigiero, L., Beerman, T. A., and Konopa, J. Induction of DNA-protein crosslinks by antitumor 1-nitro-9-aminoacridines in L1210 cells, *Biochem. Pharmacol.* 38: 4095-4101, 1989.
38. McHugh, M. M., Woynarowski, J. M., Sigmund, R. D., and Beerman, T. A. The effect of minor groove binding drugs on mammalian Topoisomerase I activity, *Biochem. Pharmacol.* 38: 2323-2328, 1989.
39. Ferguson, P. J., Fisher, M. H., Stephenson, J., Li, D., Zhou, B., and Cheng, Y. Combined Modalities of Resistance in Etoposide-resistant Human KB Cell Lines, *Cancer Res.* 48: 5956-5964, 1988.
40. Beidler, D. R., Chang, J.-Y., Zhou, B., and Cheng, Y. Camptothecin Resistance Involving Steps Subsequent to the Formation of Protein-Linked DNA Breaks in Human Camptothecin-resistant KB Cell Lines, *Cancer Res.* 56: 345-353, 1996.
41. Gekeler, V., Ise, W., Sanders, K. H., Ulrich, W. R., and Beck, J. The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance, *Biochem. Biophys. Res. Commun.* 208: 345-352, 1995.

42. Wall, M. E. Plant Antitumor Agents, V. Alkaloids with Antitumor Activity. *In*: K. Mothes, K. Schreiber, and H. R. Schutte (eds.), Symposiumberichtes, 4. Internations Symposium, Biochemie und Physiologie der Alkaloide, pp. 77-87. Berlin: Akademie-Verlag, 1969.
43. Woynarowski, J. M., Sigmund, R. D., and Beerman, T. A. DNA minor groove binding agents interfere with topoisomerase II-mediated lesions induced by epipodophyllotoxin derivative VM-26, and an acridine derivative, m-AMSA in nuclei, *Biochemistry*. 28: 3850-3855, 1989.
44. Beerman, T. A., Woynarowski, J. M., Sigmund, R. D., Gawron, L. S., and Lown, J. W. Netropsin and bis-netropsin analogs as inhibitors of the catalytic activity of mammalian DNA-topoisomerase II and topoisomerase cleavable complexes, *Biochim. Biophys. Acta*. 1090: 52-60, 1991.
45. Mattern, M. R., Mong, S. M., Bartus, H. F., Marabelli, C. K., Crooke, S. T., and Johnson, R. K. Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells, *Cancer Res*. 47: 1793-1798, 1987.



DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MARYLAND 21702-5012

REPLY TO
ATTENTION OF:

MCMR-RMI-S (70-1y)

26 Jan 01

MEMORANDUM FOR Administrator, Defense Technical Information
Center, ATTN: DTIC-OCA, 8725 John J. Kingman
Road, Fort Belvoir, VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for Grant DAMD17-96-1-6008. Request the limited distribution statement for Accession Document Number ADB225820 be changed to "Approved for public release; distribution unlimited." This report should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Judy Pawlus at DSN 343-7322 or by email at judy.pawlus@det.amedd.army.mil.

FOR THE COMMANDER:


for PHYLLIS M. RINEHART
Deputy Chief of Staff for
Information Management